NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

$76.37

-0.18 (-0.24 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$76.07

Now: $76.37▼

$76.66

50-Day Range

$73.80

MA: $79.51▼

$83.98

52-Week Range

$65.25

Now: $76.37▼

$92.64

Volume6.06 million shs

Average Volume10.53 million shs

Market Capitalization$192.77 billion

P/E Ratio19.33

Dividend Yield3.19%

Beta0.5

Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Merck & Co., Inc. has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $93.60, Merck & Co., Inc. has a potential upside of 22.6% from its current price of $76.37.
Amount of Analyst Coverage
Merck & Co., Inc. has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
Merck & Co., Inc. has received 847 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck & Co., Inc. has received 827 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck & Co., Inc. has received 50.60% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote “Outperform” if you believe MRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Leadership
Merck & Co., Inc. is a leading dividend payer. It pays a dividend yield of 3.19%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Merck & Co., Inc. has been increasing its dividend for 8 years.
Dividend Coverage
The dividend payout ratio of Merck & Co., Inc. is 47.01 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 42.66 % next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck & Co., Inc. insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $380,100.00 in company stock.
Percentage Held by Insiders
Only 0.28% of the stock of Merck & Co., Inc. is held by insiders.
Percentage Held by Institutions
75.25% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Merck & Co., Inc. are expected to grow by 7.72% in the coming year, from $5.31 to $5.72 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merck & Co., Inc. is 19.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.51.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck & Co., Inc. is 19.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.63.
Price to Earnings Growth Ratio
Merck & Co., Inc. has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Merck & Co., Inc. has a P/B Ratio of 7.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:MRK

Previous Symbol

CUSIP58933Y10

CIK310158

Webwww.merck.com

Phone908-740-4000

Debt

Debt-to-Equity Ratio0.82

Current Ratio1.11

Quick Ratio0.87

Price-To-Earnings

Trailing P/E Ratio19.33

Forward P/E Ratio14.38

P/E Growth2.12

Sales & Book Value

Annual Sales$46.84 billion

Price / Sales4.12

Cash Flow$6.69 per share

Price / Cash Flow11.41

Book Value$10.42 per share

Price / Book7.33

Profitability

EPS (Most Recent Fiscal Year)$5.19

Net Income$9.84 billion

Net Margins21.10%

Return on Equity52.46%

Return on Assets16.67%

Miscellaneous

Employees71,000

Outstanding Shares2,524,100,000

Market Cap$192.77 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock been impacted by COVID-19 (Coronavirus)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have decreased by 3.6% and is now trading at $76.37. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merck & Co., Inc.?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Merck & Co., Inc..

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings data on Tuesday, April, 28th. The company reported $1.50 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.34 by $0.16. The firm had revenue of $12.06 billion for the quarter, compared to analysts' expectations of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. Merck & Co., Inc.'s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 EPS. View Merck & Co., Inc.'s earnings history.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Wednesday, January 29th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.61 per share on Tuesday, April 7th. This represents a $2.44 annualized dividend and a dividend yield of 3.19%. The ex-dividend date is Friday, March 13th. View Merck & Co., Inc.'s dividend history.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its Board of Directors has initiated a share buyback program on Thursday, October 25th 2018, which authorizes the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 5.1% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, April, 28th. The company provided earnings per share guidance of 5.17-5.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $46.1-48.1 billion, compared to the consensus revenue estimate of $48.72 billion.

What price target have analysts set for MRK?

15 Wall Street analysts have issued 12 month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $85.00 to $105.00. On average, they expect Merck & Co., Inc.'s share price to reach $93.60 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

Has Merck & Co., Inc. been receiving favorable news coverage?

Media coverage about MRK stock has been trending extremely negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutMerck & Co., Inc..

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 18,890,000 shares, a decline of 8.3% from the April 30th total of 20,610,000 shares. Based on an average trading volume of 13,820,000 shares, the short-interest ratio is presently 1.4 days. Approximately 0.8% of the shares of the stock are short sold. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
Mr. Adam H. Schechter, Special Advisor (Age 54)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.74%), State Street Corp (4.65%), Wellington Management Group LLP (1.90%), Geode Capital Management LLC (1.58%), Capital World Investors (1.51%) and Bank of New York Mellon Corp (1.37%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital International Investors, Wellington Management Group LLP, Nuveen Asset Management LLC, Assenagon Asset Management S.A., APG Asset Management N.V., Eaton Vance Management, and 1832 Asset Management L.P.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, Robert M Davis, and Wendell P Weeks. View insider buying and selling activity for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, BlackRock Inc., Federated Hermes Inc., Swiss National Bank, The Manufacturers Life Insurance Company , Cullen Capital Management LLC, Unigestion Holding SA, and Franklin Resources Inc.. View insider buying and selling activity for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $76.37.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $192.77 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff